Platelet-derived micro particles during and after acute coronary syndrome

Thrombosis and Haemostasis

Volumn 107, Issue 6, 2012, Pages 1122-1129

  Skeppholm, Mika ^a   Mobarrez, Fariborz ^a   Malmqvist, Karin ^a   Wallén, Håkan ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Ischaemic heart disease; Microparticles; P selectin; Phosphatidylserine; Tissue factor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CD142 ANTIGEN; CD61 ANTIGEN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; ENOXAPARIN; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; PADGEM PROTEIN; PHOSPHATIDYLSERINE; SPIRONOLACTONE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AUTACOID; BETA3 INTEGRIN; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; IL6 PROTEIN, HUMAN; ITGB3 PROTEIN, HUMAN; SELP PROTEIN, HUMAN; THROMBOPLASTIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PLATELET MICROPARTICLE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; UNSTABLE ANGINA PECTORIS; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; DRUG EFFECT; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; PARTICLE SIZE; PATHOLOGY; SWEDEN; THROMBOCYTE; TIME;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD PLATELETS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; FLOW CYTOMETRY; HUMANS; INFLAMMATION MEDIATORS; INTEGRIN BETA3; INTERLEUKIN-6; MALE; MIDDLE AGED; P-SELECTIN; PARTICLE SIZE; PHOSPHATIDYLSERINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; SWEDEN; THROMBOPLASTIN; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84861745672     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-11-0779     Document Type: Article

References (29)

1. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc 2010; 303: 754-762.
2. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl 1): S13-S33.
3. VanWijk MJ, VanBavel E, Sturk A, et al. Microparticles in cardiovascular diseases. Cardiovasc Res 2003; 59: 277-287.
4. Burnier L, Fontana P, Kwak BR, et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-451.
5. Perez-Pujol S, Marker PH, Key NS. Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A 2007; 71: 38-45.
6. van der Zee PM, Biró E, Ko Y, et al. P-selectin- and CD63-exposing platelet micro-particles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 2006; 52: 657-664.
7. Hou J, Fu Y, Zhou J, et al. Lactadherin functions as a probe for phosphatidylserine exposure and as an anticoagulant in the study of stored platelets. Vox Sang 2011; 100: 187-195.
8. Sinauridze EI, Kireev DA, Popenko N Y, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-434.
9. Connor DE, Exner T, Ma DF, et al. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 2010; 103: 1044-1052.
10. Morel O, Hugel B, Jesel L, et al. Sustained elevated amounts of circulating pro-coagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost 2004; 91: 345-353.
11. Morel O, Hugel B, Jesel L, et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Hae-most 2004; 2: 1118-1126.
12. Skeppholm M, Kallner K, Malmqvist K, et al. Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res 2011; 128: 483-489.
13. Mobarrez F, Antovic J, Egberg N, et al. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thromb Res 2010; 125: e110-116.
14. Mobarrez F, Egberg N, Bröijersen A, et al. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb Res 2012; 129: 95-97.
15. Mobarrez F, He S, Bröijersen A, et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived micro-particles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011; 106: 344-352.
16. Gawaz M, Neumann FJ, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-237.
17. Flaumenhaft R, Dilks JR, Richardson J, et al. Megakaryocyte-derived micropar-ticles: direct visualization and distinction from platelet-derived microparticles. Blood 2009; 113: 1112-1121.
18. Owens A P, Mackman N. Microparticles in Hemostasis and Thrombosis. Circ Res 2011; 108: 1284-1297.
19. Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-175.
20. Schwertz H, Tolley ND, Foulks JM, et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med 2006; 203: 2433-2440.
21. Steppich BA, Braun SL, Stein A, et al. Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. Thromb J 2009; 7: 11.
22. Serebruany VL, Malinin AI, Jerome SD, et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003; 146: 713-720.
23. Nomura S, Takahashi N, Inami N, et al. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis 2004; 174: 329-335.
24. Rank A, Nieuwland R, Crispin A, et al. Clearance of platelet microparticles in vivo. Platelets 2011; 22: 111-116.
25. Bulut D, Becker V, Mügge A. Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can. J. Physiol. Pharmacol 2011; 89: 239-244.
26. Trip MD, Cats VM, van Capelle FJ, et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554.
27. Mallat Z, Steg G, Hugel B, et al. Prognostic value of circulating shed membrane pro-coagulant microparticles in patients with severe acute coronary syndromes. A substudy from the global registry of acute coronary events (GRACE). Circulation 2004; 110 (Suppl S): 575. (Abstract).
28. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: Disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol.2006; 26: 2594-2604.
29. Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011; 105: 396-408.